C. Logan

Structure determination of LpxD from the lipopolysaccharide-synthesis pathway of Acinetobacter baumannii.

P. Zwart, B. Sankaran, V. Nienaber, 2012, Acta crystallographica. Section F, Structural biology and crystallization communications.

The structure of LpxD from Pseudomonas aeruginosa at 1.3 Å resolution.

P. Zwart, B. Sankaran, V. Nienaber, 2011, Acta crystallographica. Section F, Structural biology and crystallization communications.

Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.

P. Hipskind, D. Clawson, D. Manglicmot, 2015, Journal of medicinal chemistry.

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787

P. Y. Ayala, V. Nienaber, P. Petluru, 2015, OncoTargets and therapy.

Structure determination of LpxA from the lipopolysaccharide-synthesis pathway of Acinetobacter baumannii.

P. Zwart, B. Sankaran, V. Nienaber, 2012, Acta crystallographica. Section F, Structural biology and crystallization communications.

Identification and Optimization of PDE10A Inhibitors Using Fragment-Based Screening by Nanocalorimetry and X-ray Crystallography

V. Nienaber, M. Recht, Francisco E. Torres, 2014, Journal of biomolecular screening.

Structure determination of LpxA from the lipopolysaccharide-synthesis pathway of Acinetobacter baumannii.

P. Zwart, B. Sankaran, V. Nienaber, 2012, Acta crystallographica. Section F, Structural biology and crystallization communications.

Novel covalent modification of human anaplastic lymphoma kinase (ALK) and potentiation of crizotinib-mediated inhibition of ALK activity by BNP7787

P. Y. Ayala, V. Nienaber, P. Petluru, 2015, OncoTargets and therapy.